Business Process Services

Life Sciences and Healthcare Services

Today, the pharmaceutical industry is dealing with reduced profits caused by a diminishing pipeline, increasing R&D costs, expiring patents and rapidly changing regulatory environment. Along with these, quicker drug discovery and drug launch, competition from generics have perpetuated the need for efficient clinical services.

TCS, with its deep domain knowledge in Clinical Services coupled with industry leading technology and analytics solutions ensures faster drug development, improved patient outcomes while managing cost efficiency.


Client Experience: AstraZeneca
Watch Vita M Petrik, Interface Lead – Patient Safety, AstraZeneca, discusses how AstraZeneca’s partnership with TCS enabled it to focus on its core activities, by helping it manage its pharmacovigilance processes.


The TCS Advantage

Our ValueBPS approach helps enterprises achieve significant and sustained business outcomes by leveraging our deep domain expertise and operations redesign methodologies such as FORE™. Our approach also encompasses robotic process automation (RPA), analytics and insights, our unique IT-BPS synergy, Business Process as a Service (BPaaS) models, and business process management (BPM).

TCS is the preferred partner in the Clinical Services for 12 of the Top 20 Global Pharmaceutical Companies. Our proprietary suite of delivery excellence tools help improve productivity and efficiency, accelerating the decision making process for life science companies. Our Global domain network model ensures geographic coverage, multi-language capabilities, and local affiliate support.

Solutions We Offer

Pharmacovigilance Services
Our pharmacovigilance service helps you to meet safety practices which include data collection, case processing, medical review, quality review, regulatory submission, Safety report writing and Safety surveillance activities  ensuring a comprehensive coverage of your safety operation with complete regulatory compliance.

Clinical Data Management Services
Our clinical data management services helps you to meet end-to-end data management which include clinical study setup, study conduct and study closure generating high-quality, reliable, and statistically sound data from clinical trials. This helps to reduce time from drug development to marketing.

Regulatory Services
Our regulatory services helps you to meet your global regulatory submissions and regulatory information management requirements, thereby helps you in compliance and regulatory intelligence for drug development.

Biostatistics and Statistical Programming Services
Our end to end biostatistics and statistical programming services helps you design, analysis, reporting and interpretation of clinical trial data across wide range of therapeutic areas from Phase I to Phase IV thereby ensuring high quality of study design and resulting data.

Medical Writing and Publishing Services
Our medical expertise in writing regulatory, scientific and medico-marketing documents helps you for preparing submission-ready documents of pharmaceutical products for more than 13 therapeutic areas for submission to regulatory authorities across the globe.

Our capabilities are further strengthened by:


TCS’ Clinical Services helps drug companies to improve quality and efficiency in trials and reduce costs by decreasing management oversight from sponsors.

Some of the benefits delivered to our partners are:

  • Over 99% compliance for case processing
  • Over 50% improvement in productivity and increased regulatory compliance
  • Over 90% reduction in  turnaround time for publishing activities
  • Up to 50% cost savings through TCS’ proprietary tools

Click here to know about our healthcare services.

Reach Us.



Press Releases

TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape

Tata Consultancy Services (TCS) has been designated as a Leader in Worldwide Life Sciences R&D Risk-Based Monitoring by global market intelligence firm, IDC, in the “IDC MarketScape: Worldwide Life Science R&D Risk-Based Monitoring 2015 Vendor Assessment,” (doc #HI255628, April 2015) report.